We report a new air‐stable PdI dimer, [Pd(μ‐I)(PCy2tBu)]2, which triggers E‐selective olefin migration to enamides and styrene derivatives in the presence of multiple functional groups and with complete tolerance of air. The same dimer also triggers extremely rapidC−Ccoupling (alkylation and arylation) at roomtemperature in a modular and triply selective fashion of aromatic C−Br, C−OTf/OFs, and
我们报告了一种新的空气稳定的Pd I二聚体[Pd(μI)(PCy 2 t Bu)] 2,它在存在多个官能团且具有完全耐受性的情况下触发E-选择性烯烃向酰胺和苯乙烯衍生物的迁移空气 同一二聚体还可以在室温下以模块化和三重选择性的方式在聚(假)卤代芳烃中以芳族C-Br,C-OTf / OF和C-Cl键的形式快速触发C-C偶联(烷基化和芳基化)在具有邻位C-OTf的取代基的底物上显示出比以前的Pd I二聚体更好的活性。
Facile and selective synthesis of chloronicotinaldehydes by the Vilsmeier reaction
prepared were subjected to Vilsmeierreaction using (i) POCl3/DMF; (ii) diphosgene/DMF; (iii) triphosgene/DMF leading to the formation of various multisubstituted chloronicotinaldehydes. Studies carried out indicate that Vilsmeier reagent concentration and the replacement of POCl3 by diphosgene or triphosgene, provides excellent selectivity and higher yields. Under modified reaction conditions one can get
The [Rh2(OAc)4] catalysed hydrosilylation of enamides and N-vinylureas with dimethylphenylsilane proceeds smoothly in a regio- and site-selective manner to give 1-(trialkylsilyl)alkylamine derivatives in good to high yields.
HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
申请人:Hutchinson John Howard
公开号:US20110319445A1
公开(公告)日:2011-12-29
Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
Heteroaryl antagonists of prostaglandin D2 receptors
申请人:Hutchinson John Howard
公开号:US08378107B2
公开(公告)日:2013-02-19
Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.